Entering text into the input field will update the search result below

MiNK begins dosing in phase 1 trial of AgenT-797 cell therapy for solid tumors

Mar. 03, 2022 1:29 PM ETMiNK Therapeutics, Inc. (INKT)By: Ravikash, SA News Editor

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

  • MiNK Therapeutics (INKT +1.2%) began dosing in a phase 1 trial of AgenT-797 iNKT cell therapy alone and in combination with approved anti-PD-1 checkpoint inhibitors in patients with relapsed/refractory solid tumors.
  • The company said pre-clinical data

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About INKT

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MiNK Therapeutics, Inc.
Enlivex Therapeutics Ltd.
Achilles Therapeutics plc
BeyondSpring Inc.
Passage Bio, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.